ASCO: A 'Home Run' in Prostate Cancer Tx

CHICAGO (MedPage Today) -- Overall survival in metastatic prostate cancer improved by more than a year when patients received docetaxel at the start of androgen deprivation therapy, according to trial results that oncologists here called "unprecedented" and a "home run."
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news